Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10604860 | 1.00 | ACE (0.53) | ACEPPARAPPARGITGB3ITGA2B | |
| SCHEMBL10632464 | 0.92 | ACE (0.49) | ACEPPARAPPARGITGB3ITGA2B | |
| SCHEMBL10632461 | 0.92 | ACE (0.49) | ACEPPARAPPARGITGB3ITGA2B | |
| SCHEMBL1055585 | 0.90 | ACE (0.52) | ACEPPARAPPARGITGB3ITGA2B | |
| SCHEMBL2263756 | 0.90 | ACE (0.52) | ACEPPARAPPARGITGB3ITGA2B | |
| SCHEMBL21062787 | 0.88 | ACE (0.50) | ACEPPARAPPARGITGB3ITGA2B | |
| SCHEMBL9728451 | 0.88 | ACE (0.50) | ACEPPARAPPARGITGB3ITGA2B | |
| SCHEMBL1055857 | 0.87 | ACE (0.49) | ACEPPARAPPARGITGB3ITGA2B | |
| SCHEMBL1055858 | 0.87 | ACE (0.49) | ACEPPARAPPARGITGB3ITGA2B | |
| SCHEMBL10477404 | 0.86 | ACE (0.56) | ACEPPARAPPARGITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361987-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | STEALTH BIOTHERAPEUTICS INC. | 2020-11-19 | — | — | US | disclosed |
| US-9982014-B2 | Tetrapeptide compound and method for producing same | KANEKA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20160264623-A1 | TETRAPEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME | STEALTH BIOTHERAPEUTICS INC. | 2016-09-15 | — | — | US | disclosed |
| US-7727991-B2 | Substituted melanocortin receptor-specific single acyl piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20060287330-A1 | Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-5216124-A | Analgesics | G. D. SEARLE & CO. (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0136720-B1 | ENKEPHALIN ANALOGS | G.D. Searle & Co. (US) | 1989-09-20 | — | — | EP | disclosed |
| US-4760180-A | N-terminally substituted dipeptide amides | G. D. SEARLE & CO. (US) | 1988-07-26 | — | — | US | disclosed |
| US-4722922-A | RENIN INHIBITION | G. D. SEARLE & CO. (US) | 1988-02-02 | — | — | US | disclosed |
| EP-0213481-A2 | N-terminally substituted dipeptide amides No. 2 | G.D. Searle & Co. (US) | 1987-03-11 | — | — | EP | disclosed |
| US-4603121-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1986-07-29 | — | — | US | disclosed |
| EP-0136720-A2 | Enkephalin analogs | G.D. Searle & Co. (US) | 1985-04-10 | — | — | EP | disclosed |
| US-4495178-A | Enkephalin analogs | G. D. SEARLE & CO. (US) | 1985-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287330-A1 | Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds | MC4R, MC5R, MC3R | ACE 4337/4885PPARA 241/4885PPARG 205/4885 |
| US-20160264623-A1 | TETRAPEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME | VIP, DNPEP, PEPD | ACE 537/4885PPARA 3757/4885PPARG 4293/4885 |
| US-20200361987-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | ABAT, SSBP1, PDF | ACE 3998/4885PPARA 1266/4885PPARG 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.